Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines

BACKGROUND: Temsirolimus is a mammalian target of rapamycin (mTOR) inhibitor and rapamycin analogue that is approved for treating advanced renal cell carcinoma (RCC). It is being actively evaluated in clinical trials for melanoma. The mTOR inhibitors are also immunosuppressants and are used clinical...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Wang, Y, Wang, X-Y, Subjeck, J R, Shrikant, P A, Kim, H L
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2011
Assuntos:
Translational Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3049595/
https://ncbi.nlm.nih.gov/pubmed/21285988
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.15
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares